Pharma Deals Review, Vol 2007, No 87 (2007)

Font Size:  Small  Medium  Large

Enzon Pharmaceuticals Sells 25% Interest in Hepatitis C Drug

Business Review Editor

Abstract


Enzon Pharmaceuticals has sold 25% of its royalty in PEG-Intron® to Drug Royalty for US$92.5 M. PEG-Intron® is an interferon alpha for the treatment for hepatitis C.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.